Biotech Values

[walldiver]

The data mining at INGN is far more egregious than the data mining ALTH did a few years ago. For one thing, ALTH actually ran a pivotal Phase III. They picked the wrong subgroup to try and get approval for, however. The brain mets from breast cancer subgroup comprised approx 25% of the ITT group. At least ALTH is now running a pivotal Phase III w/SPA for that subgroup. Probably a coin flip for stat sig.

In addition, ALTH has not done a reverse split. They've diluted somewhat, but the price is ~3 1/2 times where it was in May 2004 after they got thumbs down at ODAC. INGN's subgroup comprised approx 5-10% of the ITT group in its Phase III. Not only that, but the co is trying to cherry-pick patients from some of its Phase II trials in order to add them all together into a collective group to present to the FDA. The company is a scam, IMO.